Search research articles
Contact Us
Filters
Showing results (41-50 of 73) with videos related to
Page
of 8
Sort By:
Blood Cancer Journal
|
February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.
JAMA Internal Medicine
|
October 1, 2020
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial
Benjamin S Abella, Eliana L Jolkovsky, Barbara T Biney, et al.
Blood
|
April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma
Sarah A Holstein, Shebli Atrash, Hira Mian, et al.
Haematologica
|
March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Michel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 3, 2014
Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma
Ravi Vij, Shaji Kumar, Mei-Jie Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
Marcelo C Pasquini, Paul K Wallace, Brent Logan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
Alexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
The Lancet. Oncology
|
October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Edward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
Clinical Chemistry
|
August 12, 2021
Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking
Hui Chen, Zhao Li, Sheng Feng, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 73) with videos related to
Sort By:
Page
of 8
Blood Cancer Journal
|
February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.
JAMA Internal Medicine
|
October 1, 2020
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial
Benjamin S Abella, Eliana L Jolkovsky, Barbara T Biney, et al.
Blood
|
April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma
Sarah A Holstein, Shebli Atrash, Hira Mian, et al.
Haematologica
|
March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Michel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 3, 2014
Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma
Ravi Vij, Shaji Kumar, Mei-Jie Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
Marcelo C Pasquini, Paul K Wallace, Brent Logan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
Alexander E Perl, Margaret T Kasner, Donald E Tsai, et al.
The Lancet. Oncology
|
October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Edward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
Clinical Chemistry
|
August 12, 2021
Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking
Hui Chen, Zhao Li, Sheng Feng, et al.
Page
of 8